China Healthwise Holdings Ltd (0348) Fair Value & Analysis

Healthcare · HK · Market cap HK$43.1M (≈ $5.5M) · ISIN KYG2120E1290

What is China Healthwise Holdings Ltd really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.

How to read this chart

60‑month range HK$0.0340 – HK$0.3850 · fair‑value band HK$0.0470 – HK$0.0722 · the HK$0.0700 price screens above the HK$0.0638 fair value. Dashed = 300-day average. As of Aug 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

China Healthwise Holdings Ltd (0348) currently trades at HK$0.0700, while our model-based Fair Value estimate is HK$0.0638, implying the stock looks roughly 9.7% fairly valued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of HK$0.0600 per share, and 0 of the 9 models we run sit above the HK$0.0700 price. Bear case: the Dividend Discount group reads lowest at HK$0.0200, and 9 of the 9 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, China Healthwise Holdings Ltd generated revenue of HK$99.6M at a net margin of −2.6%. Revenue declined 7.9% year over year. Net debt stands at HK$96.9M. Fundamentals as of Aug 17, 2026

Our scenario range runs from HK$0.0470 (bear case) to HK$0.0722 (bull case); at HK$0.0700, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 68% below its 52-week high and 37% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at −9%, 0348 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: Multiples (HK$0.0600) versus Dividend Discount (HK$0.0200). Highest evidence: FCF DCF (82).

Key figures & financial health

Quality Score breakdown

About the company

China Healthwise Holdings Limited, an investment holding company, engages in the sale of Chinese health products in Hong Kong. It operates through three segments: Chinese Health Products, Money Lending Business, and Investment in Financial Instruments.

Full company description

China Healthwise Holdings Limited, an investment holding company, engages in the sale of Chinese health products in Hong Kong. It operates through three segments: Chinese Health Products, Money Lending Business, and Investment in Financial Instruments. The company sells Chinese and other pharmaceutical products, health products, ginseng, and dried seafood products to wholesalers and retailers; and trades and retails Sum Yung and dried seafood under the Nam Pei Hong brand name. It is also involved in money lending business; and invests in financial instruments. The company was formerly known as Haier Healthwise Holdings Limited and changed its name to China Healthwise Holdings Limited in January 2017. China Healthwise Holdings Limited was incorporated in 1997 and is headquartered in Central, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

China Healthwise Holdings Ltd reported revenue of HK$99.6M in FY2026 versus HK$170M in FY2022, a compound −12.5%/yr. Reported net income was −HK$2.6M in FY2026.

Watch 0348: get an alert when its fair value changes →

Peer Group

Pharmaceutical Retailers · 57 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions